Treatment Wet AMD

Sponsor: RegenxBio (RGX Ascent/Atmosphere)

In this study, we are recruiting patients with wet AMD who are requiring repeated intravitreal anti-VEGF injections to maintain stability. This study utilizes a novel genetic therapy which codes for the “blueprint instructions” to teach the retinal cells to produce their own anti-VEGF molecule. This allows the eye to be its own factory of medication thus reducing the need for repeated injections. The genetic therapy is injected under the retina during a one-time surgical procedure. Initial studies have shown both a favorable efficacy and safety profile.

For more information visit www.REGENXBIO.com